JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Kura Oncology Inc

Atvērts

SektorsVeselības aprūpe

5.64 1.62

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

5.45

Max

5.71

Galvenie mērījumi

By Trading Economics

Ienākumi

-38M

-57M

Pārdošana

-40M

14M

Peļņas marža

-407.067

Darbinieki

192

EBITDA

-48M

-65M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+357.22% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

21M

547M

Iepriekšējā atvēršanas cena

4.02

Iepriekšējā slēgšanas cena

5.64

Ziņu noskaņojums

By Acuity

50%

50%

162 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Kura Oncology Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 11. aug. 17:49 UTC

Galvenie tirgus virzītāji

180 Life Sciences Stock Jumps on $156 Million Notes Sale

2025. g. 11. aug. 17:18 UTC

Galvenie tirgus virzītāji

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

2025. g. 11. aug. 16:25 UTC

Peļņas

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

2025. g. 11. aug. 23:50 UTC

Tirgus saruna

Nikkei May Rise as Yen Weakens -- Market Talk

2025. g. 11. aug. 23:42 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 11. aug. 23:42 UTC

Tirgus saruna

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

2025. g. 11. aug. 23:36 UTC

Tirgus saruna

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2025. g. 11. aug. 23:32 UTC

Tirgus saruna

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

2025. g. 11. aug. 23:02 UTC

Tirgus saruna

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

2025. g. 11. aug. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 11. aug. 20:37 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

2025. g. 11. aug. 20:37 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Bakkt Holdings 2Q Rev $577.9M >BKKT

2025. g. 11. aug. 20:37 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement 2Q Rev $25.8M >EXOD

2025. g. 11. aug. 20:14 UTC

Tirgus saruna

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

2025. g. 11. aug. 19:12 UTC

Tirgus saruna

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

2025. g. 11. aug. 18:56 UTC

Tirgus saruna

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

2025. g. 11. aug. 18:31 UTC

Tirgus saruna

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

2025. g. 11. aug. 17:43 UTC

Tirgus saruna

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

2025. g. 11. aug. 17:28 UTC

Tirgus saruna

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

2025. g. 11. aug. 17:16 UTC

Tirgus saruna

Commodity Longs Fall to 11-Month Low -- Market Talk

2025. g. 11. aug. 16:42 UTC

Iegādes, apvienošanās, pārņemšana

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

2025. g. 11. aug. 16:27 UTC

Iegādes, apvienošanās, pārņemšana

BBVA Says Sabadell Offer Remains in Effect

2025. g. 11. aug. 16:26 UTC

Iegādes, apvienošanās, pārņemšana

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

2025. g. 11. aug. 16:25 UTC

Iegādes, apvienošanās, pārņemšana

Banco de Sabadell Announced TSB Sale on July 1

2025. g. 11. aug. 16:25 UTC

Iegādes, apvienošanās, pārņemšana

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Salīdzinājums

Cenas izmaiņa

Kura Oncology Inc Prognoze

Cenas mērķis

By TipRanks

357.22% augšup

Prognoze 12 mēnešiem

Vidējais 25.33 USD  357.22%

Augstākais 40 USD

Zemākais 8 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Kura Oncology Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

13 ratings

11

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

5.575 / 6.6Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

162 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.